These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7741147)

  • 21. Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
    Smith KJ
    Blood; 1988 Oct; 72(4):1269-77. PubMed ID: 3262386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group.
    Shapiro A; Abe T; Aledort LM; Anderle K; Hilgartner MW; Kunschak M; Preston FE; Rivard GE; Schimpf K
    Transfusion; 1995 Mar; 35(3):204-8. PubMed ID: 7878711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction and management of adverse events associated with the use of factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):36-40. PubMed ID: 8480197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal-antibody-purified factor IX.
    Kurczynski EM; Moncino MD
    Lancet; 1993 May; 341(8853):1148. PubMed ID: 8097824
    [No Abstract]   [Full Text] [Related]  

  • 29. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological approaches to the study of the mechanism of hemostasis and thrombosis: applications of monoclonal antibodies against factor IX; a review.
    Kojima T; Takamatsu J; Sano M
    Nihon Ketsueki Gakkai Zasshi; 1987 Dec; 50(8):1697-701. PubMed ID: 3328950
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B.
    Djulbegovic B; Hannan MM; Bergman GE
    Acta Haematol; 1995; 94 Suppl 1():43-7; discussion 48. PubMed ID: 7571994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor IX and thrombosis.
    Aledort LM
    Scand J Haematol Suppl; 1977; 30():40-2. PubMed ID: 267296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
    Sultan Y; Boyeldieu D; Stieltjes N
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III.
    Hoffman C; Hultin MB
    Thromb Res; 1986 Jul; 43(2):143-51. PubMed ID: 3738857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis risk in cardiac surgery patients receiving factor IX concentrates.
    Rossiter SJ; Miller DC; Raney AA; Oyer PE; Reitz BA; Stinson EB; Shumway NE
    J Thorac Cardiovasc Surg; 1979 Aug; 78(2):203-7. PubMed ID: 459527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
    Campbell EW; Neff S; Bowdler AJ
    Transfusion; 1978; 18(1):94-7. PubMed ID: 625789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.